Teva Pharma (TEVA) Announces New Clinical and Real-World Data Evaluating Efficacy of AJOVY (fremanezumab-vfrm) Injection and Reduction of Migraine Burden

Go back to Teva Pharma (TEVA) Announces New Clinical and Real-World Data Evaluating Efficacy of AJOVY (fremanezumab-vfrm) Injection and Reduction of Migraine Burden

New Clinical and Real-World Data Evaluating Efficacy of AJOVY® (fremanezumab-vfrm) Injection and Reduction of Migraine Burden Presented at 2021 American Academy of Neurology Virtual Annual Meeting

April 19, 2021 8:00 AM EDT

Findings describe long-term and real-world data across post-hoc and retrospective analyses

TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data from clinical and real-world analyses examining the efficacy of AJOVY® (fremanezumab-vfrm). These data are being presented at the 2021 American Academy of Neurology (AAN) Virtual Annual... More